New combo shows promise for tough head and neck cancers
NCT ID NCT00939627
First seen Mar 17, 2026 · Last updated Jun 15, 2026 · Updated 15 times
Summary
This study looked at 55 people with advanced head and neck cancer that had come back or spread. It compared the drug cetuximab alone versus cetuximab plus sorafenib to see which worked better at slowing the cancer. The goal was to find a more effective treatment option for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TONGUE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Billings Clinic
Billings, Montana, 59107-7000, United States
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Montefiore Medical Center
The Bronx, New York, 10467-2490, United States
-
Suburban Hospital
Bethesda, Maryland, 20814, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.